-
601
-
602
-
603
Identifying key transcription factors and miRNAs coregulatory networks associated with immune infiltrations and drug interactions in idiopathic pulmonary arterial hypertension
Published 2023-01-01“…Also, we employed a molecular docking approach to evaluate the potential protein-drug interactions. Results: We found that 14 TFs encoding genes, including ZNF83, STAT1, NFE2L3, and SMARCA2 are upregulated, and 47 TFs encoding genes, including NCOR2, FOXA2, NFE2, and IRF5 are downregulated in IPAH relative to the control. …”
Get full text
Article -
604
Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine
Published 2022-11-01“…To illustrate the performance of the developed RIV PBPK model on the prediction of drug–drug interactions (DDIs), carbamazepine (CBZ) was selected as a case study due to the high DDI potential. …”
Get full text
Article -
605
Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug–drug interactions via CYP3A metabolism and transporters
Published 2023-04-01“…Based on nonclinical in vitro characterization of gepotidacin metabolism, two phase I studies were conducted in healthy participants to investigate clinical drug–drug interactions (DDIs). We assessed gepotidacin as a DDI victim with a potent cytochrome P450 (CYP) 3A4/P‐glycoprotein (P‐gp) inhibitor (itraconazole), potent CYP3A4 inducer (rifampicin), and nonspecific organic cation transporter (OCT)/multidrug and toxic extrusion transporter (MATE) renal transport inhibitor (cimetidine) via single doses of gepotidacin before and after co‐administration with multiple doses of the modulator drugs. …”
Get full text
Article -
606
Drug binding and drug-drug interaction considerations in individuals with obesity before and after bariatric surgery: A retrospective cross-sectional study
Published 2023-06-01“…Before surgery, it was found that more than half of the patients had at least one drug interaction in their therapeutic regimen. Of these, most were classified as moderate. …”
Get full text
Article -
607
COMPARATIVE ANALYSIS OF DRUG EFFICACY IN THE TREATMENT FOR COVID-19 SEVERE FORMS, BASED ON ATTRIBUTE-BASED STATISTIC METHODS AND ANALYSIS OF DRUG INTERACTIONS
Published 2021-03-01“…The safety of the drug use was assessed by analyzing potential drug interactions. The information about potential drug interactions, was obtained from a specialized website – Drugs.com. …”
Get full text
Article -
608
-
609
-
610
Acute massive pulmonary embolism in a patient using clavis panax
Published 2013-06-01Subjects: “…herb-drug interactions…”
Get full text
Article -
611
Polypharmacy in Type 2 Diabetes Mellitus: Insights from an Internal Medicine Department
Published 2019-08-01Subjects: Get full text
Article -
612
-
613
Pharmacokinetic Herb-Drug Interactions of Glipizide with <i>Andrographis paniculata</i> (Burm. f.) and Andrographolide in Normal and Diabetic Rats by Validated HPLC Method
Published 2022-10-01Subjects: “…herb–drug interactions…”
Get full text
Article -
614
Evaluation of pharmacological and pharmacokinetic herb-drug interaction between irinotecan hydrochloride injection and Kangai injection in colorectal tumor-bearing mice and healthy rats
Published 2023-11-01Subjects: “…herb-drug interaction…”
Get full text
Article -
615
Novel Method for Early Prediction of Clinically Significant Drug–Drug Interactions with a Machine Learning Algorithm Based on Risk Matrix Analysis in the NICU
Published 2022-08-01Subjects: “…drug–drug interactions…”
Get full text
Article -
616
Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics
Published 2022-01-01“…Abstract Xenobiotics can interact with cytochromes P450 (CYPs), resulting in drug–drug interactions, but CYPs can also contribute to drug–disease interactions, especially in the case of inflammation, which downregulates CYP activities through pretranscriptional and posttranscriptional mechanisms. …”
Get full text
Article -
617
A systematic review of flurbiprofen 8.75 mg dose and risk of adverse events (excluding haemorrhagic) resulting from drug-drug interactions
Published 2024-03-01Subjects: Get full text
Article -
618
-
619
-
620